WEBVTT 1 00:00:00.666 --> 00:00:03.900 Since being diagnosed with advanced colorectal cancer 2 00:00:03.900 --> 00:00:05.166 two and a half years ago, 3 00:00:05.300 --> 00:00:08.033 Sarah has gone through two different lines of treatment, 4 00:00:08.033 --> 00:00:10.333 but her disease has still gotten worse. 5 00:00:10.333 --> 00:00:15.433 She’s tired, frustrated, and doesn’t know what to do next. 6 00:00:16.166 --> 00:00:20.400 Sarah has done some research and knows that her options are most likely 7 00:00:20.400 --> 00:00:23.866 a clinical trial or an approved 3rd line of treatment. 8 00:00:24.033 --> 00:00:27.033 But the standard treatment examples she found only provided 9 00:00:27.033 --> 00:00:29.433 about 7 months of overall survival. 10 00:00:29.700 --> 00:00:34.166 That’s not enough time for Sarah. Are there other options for her? 11 00:00:35.866 --> 00:00:38.466 Her oncologist, Dr. Mendez, 12 00:00:38.466 --> 00:00:41.933 offers a plan involving LONSURF and bevacizumab, 13 00:00:42.166 --> 00:00:46.133 which were approved for use together in August 2023. 14 00:00:46.400 --> 00:00:49.166 He thinks this combination will help Sarah 15 00:00:49.166 --> 00:00:52.033 redefine her treatment expectations. 16 00:00:52.033 --> 00:00:56.033 LONSURF is an oral medication used alone or together 17 00:00:56.033 --> 00:00:59.033 with the IV-administered medicine bevacizumab 18 00:00:59.066 --> 00:01:02.066 to treat adults with colorectal cancer that has spread 19 00:01:02.066 --> 00:01:03.766 to other parts of the body,  20 00:01:03.833 --> 00:01:05.400 and who have been previously treated 21 00:01:05.400 --> 00:01:07.333 with certain chemotherapy medicines. 22 00:01:08.000 --> 00:01:13.000 Sarah asks how Dr. Mendez knows LONSURF plus bevacizumab will work. 23 00:01:14.733 --> 00:01:17.966 He tells her that results are never guaranteed and 24 00:01:17.966 --> 00:01:21.833 they can’t predict how she or her cancer will react to any treatment. 25 00:01:22.466 --> 00:01:26.633 Dr. Mendez has experience treating patients with both of these medications 26 00:01:26.633 --> 00:01:30.133 and reminds Sarah that she’s already received bevacizumab 27 00:01:30.133 --> 00:01:33.633 as part of her first and second like treatment regimens. 28 00:01:33.633 --> 00:01:37.100 But the results from the SUNLIGHT trial show that LONSURF and 29 00:01:37.100 --> 00:01:39.700 bevacizumab work well in combination, 30 00:01:39.900 --> 00:01:42.400 including for those who were previously treated with 31 00:01:42.400 --> 00:01:44.633 bevacizumab in earlier lines of treatment. 32 00:01:45.200 --> 00:01:48.200 He think this is the best option for Sarah. 33 00:01:49.333 --> 00:01:52.700 The phase 3 SUNLIGHT trial looked at the effectiveness 34 00:01:52.700 --> 00:01:57.233 and safety of LONSURF used in combination with bevacizumab compared 35 00:01:57.233 --> 00:02:00.133 to LONSURF alone for patients who had already received 36 00:02:00.133 --> 00:02:03.733 at least two types of treatment for their advanced colorectal cancer. 37 00:02:03.733 --> 00:02:07.666 SUNLIGHT’s primary focus was to study overall survival. 38 00:02:07.933 --> 00:02:10.600 Overall survival measures how long patients 39 00:02:10.600 --> 00:02:13.300 in a group taking a treatment live compared to patients 40 00:02:13.300 --> 00:02:15.133 who are taking another treatment. 41 00:02:17.666 --> 00:02:21.300 Four hundred and ninety-two patients participated in the trial. 42 00:02:21.900 --> 00:02:25.100 Two hundred and forty-six patients were treated with LONSURF 43 00:02:25.100 --> 00:02:26.933 in combination with bevacizumab 44 00:02:26.933 --> 00:02:30.700 and another 246 were given LONSURF alone. 45 00:02:31.133 --> 00:02:33.866 The group taking LONSURF + bevacizumab 46 00:02:33.866 --> 00:02:37.466 had a median overall survival rate of 10.8 months 47 00:02:37.466 --> 00:02:41.733 compared to 7.5 months in the group receiving only LONSURF. 48 00:02:43.866 --> 00:02:46.966 That means half of the patients in the combination group 49 00:02:46.966 --> 00:02:52.100 lived less than 10.8 months but the other half lived longer than that. 50 00:02:52.866 --> 00:02:55.866 So, the LONSURF + bevacizumab group saw 51 00:02:55.866 --> 00:02:58.866 a median 3.3-month improvement. 52 00:03:01.300 --> 00:03:05.033 Plus, the combination showed significant efficacy regardless 53 00:03:05.033 --> 00:03:08.800 of age, sex, tumor location, mutation type, 54 00:03:08.800 --> 00:03:11.533 and even prior bevacizumab treatment, 55 00:03:11.533 --> 00:03:14.533 making it an option for all appropriate patients. 56 00:03:15.700 --> 00:03:18.733 The possibility of 10.8 more months? 57 00:03:18.733 --> 00:03:20.533 Sarah thinks of her daughter, 58 00:03:20.533 --> 00:03:22.800 who is pregnant with her first child. 59 00:03:22.800 --> 00:03:25.800 Sarah would love to meet her grandchild. 60 00:03:26.933 --> 00:03:29.700 The numbers make Sarah more optimistic, 61 00:03:29.700 --> 00:03:32.700 but Dr. Mendez said something about safety. 62 00:03:32.700 --> 00:03:35.766 So, she asks, “How am I going to feel?” 63 00:03:36.366 --> 00:03:38.633 Dr. Mendez tells her that there is no way 64 00:03:38.633 --> 00:03:41.433 to predict exactly how she will respond to treatment. 65 00:03:41.433 --> 00:03:45.033 However, the results from the SUNLIGHT trials showed there 66 00:03:45.033 --> 00:03:47.633 were no unexpected or new side effects from taking 67 00:03:47.633 --> 00:03:51.033 LONSURF + bevacizumab versus LONSURF alone. 68 00:03:51.366 --> 00:03:54.600 You’re already familiar with bevacizumab side effects, 69 00:03:54.600 --> 00:03:58.066 but let’s review the side effects from the combination. 70 00:03:58.733 --> 00:04:01.866 The most common side effects for LONSURF when used 71 00:04:01.866 --> 00:04:04.233 in combination with bevacizumab 72 00:04:04.233 --> 00:04:08.800 include low blood counts, tiredness and weakness, 73 00:04:08.800 --> 00:04:12.366 nausea, certain abnormal liver function blood tests, 74 00:04:12.366 --> 00:04:18.800 decreased sodium in your blood, diarrhea, abdominal pain, and decreased appetite 75 00:04:22.033 --> 00:04:26.300 Dr. Mendez explains another tool doctors use to assess a patient’s 76 00:04:26.300 --> 00:04:29.800 wellbeing called the ECOG Performance Status Scale. 77 00:04:30.133 --> 00:04:33.900 The ECOG Performance Status Score is a way to measure how well a 78 00:04:33.900 --> 00:04:37.800 patient is functioning in daily life, including things like taking care of 79 00:04:37.800 --> 00:04:40.466 themselves, walking around, or working. 80 00:04:40.733 --> 00:04:46.400 On the scale, 0 means someone is fully active and has no restrictions while 81 00:04:46.400 --> 00:04:48.566 5 means they have passed away. 82 00:04:48.566 --> 00:04:53.100 So, the lower your ECOG Performance Score, the better. 83 00:04:53.800 --> 00:04:56.433 In the LONSURF + bevacizumab group, 84 00:04:56.433 --> 00:05:02.233 the median time to the ECOG scale going from 0 or 1 to 2 or more 85 00:05:02.300 --> 00:05:04.233 was 9.3 months. 86 00:05:04.233 --> 00:05:08.300 The LONSURF only group had a median time of 6.3 months. 87 00:05:08.466 --> 00:05:12.766 So patients who received LONSURF + bevacizumab stayed at a lower, 88 00:05:12.766 --> 00:05:15.500 better, ECOG Performance Status longer 89 00:05:15.500 --> 00:05:18.533 than patients who received LONSURF alone. 90 00:05:18.666 --> 00:05:24.200 With LONSURF + bevacizumab, Sarah may have a better chance of living longer, 91 00:05:24.200 --> 00:05:26.966 and a better chance to be active longer, 92 00:05:26.966 --> 00:05:30.466 and no unexpected side effects were seen in the trial. 93 00:05:30.700 --> 00:05:33.266 Sarah still has a lot she wants to do. 94 00:05:33.266 --> 00:05:36.566 So, with the positive results seen in the SUNLIGHT trial, 95 00:05:36.566 --> 00:05:40.233 Sarah agrees to try LONSURF + bevacizumab. 96 00:05:40.366 --> 00:05:43.800 Talk to your doctor about LONSURF + bevacizumab. 97 00:05:43.800 --> 00:05:46.333 Because there is hope for more time and 98 00:05:46.333 --> 00:05:48.800 more of what you’re looking forward to.